Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I'm still ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

CRISPR Therapeutics' stock decline is likely ... and Transfusion-Dependent Beta Thalassemia (TDT) early on. Despite this similarity, the two companies are not similarly situated.

CRISPR Therapeutics and Vertex Pharmaceuticals ... to face the toxicity challenges of autologous transplant in SCD and beta-thalassemia patients. With regard to in-vivo therapies, the company ...

CRISPR Therapeutics is a mid-stage biotech specializing ... its CRISPR medicine for sickle cell and beta thalassemia.

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...

Shares of CRISPR Therapeutics CRSP have lost more than ... and transfusion-dependent beta-thalassemia (TDT) — in the United States and Europe. Both SCD and TDT indications have a significant ...